Form 4: Entera Bio COO Receives Stock-Settled RSU Grant

Entera Bio Ltd. Chief Operating Officer Hillel Galitzer was granted 72,993 restricted stock units in lieu of a cash bonus.

Summary

• Hillel Galitzer, Chief Operating Officer of Entera Bio Ltd., received a grant of 72,993 stock-settled restricted stock units (RSUs).
• The grant was approved by the Board of Directors on May 7, 2026.
• The RSUs were issued in lieu of a cash bonus previously owed to the executive.
• The units vest ratably on a quarterly basis over a one-year period starting May 1, 2026.
• Following this transaction, the reporting person's total beneficial ownership is 163,566 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event; it reflects standard executive compensation practices rather than a change in company fundamentals.

Positives

• Alignment of executive compensation with long-term shareholder interests through equity-based incentives.
• Preservation of company cash reserves by substituting a cash bonus with stock-settled units.

Negatives

• Dilutive impact on existing shareholders, albeit minor, due to the issuance of new equity.

Risks

• Potential for executive turnover if equity-based compensation does not meet performance expectations.
• Market volatility affecting the ultimate value of the equity granted to the executive.

Future Outlook

The RSUs will vest quarterly over a one-year period, indicating a retention strategy for the executive through mid-2027.

Management Comments

• The grant was awarded in lieu of a cash bonus the reporting person was otherwise entitled to.

Industry Context

StockSavvy.ai notes that it is common practice for small-cap biotech firms to utilize equity-based compensation to preserve cash for R&D and clinical trial operations.

Comparison to Industry Standards

• The use of stock-settled RSUs in lieu of cash is a standard cash-preservation strategy for early-stage pharmaceutical companies.
• Vesting schedules of one year are relatively short compared to standard three-to-four-year vesting periods seen in larger cap companies.

Stakeholder Impact

• Shareholders experience minor dilution.
• The COO's interests are further aligned with the company's stock performance.

Next Steps

• Quarterly vesting of the RSU grant over the next 12 months.

Key Dates

Keywords

Entera Bio, ENTX, Form 4, Insider Trading, Executive Compensation, Restricted Stock Units, Biotech